These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 38748459)
1. The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study. Xin F; Yu YH; Shen XL; Zhang GX Hematology; 2024 Dec; 29(1):2350319. PubMed ID: 38748459 [TBL] [Abstract][Full Text] [Related]
2. Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis. Huang R; He H; Xu X; Lin X; Dong Y; Wang X; Jiang F; Huang P; Mo S; Huang Z; Wang Y; Tao H; Zheng Y; Wu M; Yang C; Zheng Z; Zhao Y; Zhang Y; Li Y Cancer; 2024 Jul; 130(14):2472-2481. PubMed ID: 38470375 [TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy. Acker F; Chromik J; Tiedjen E; Wolf S; Vischedyk JB; Makowka P; Enßle JC; Kouidri K; Sebastian M; Steffen B; Oellerich T; Serve H; Neubauer A; Schäfer JA; Bittenbring JT Eur J Haematol; 2024 Nov; 113(5):623-630. PubMed ID: 39023132 [TBL] [Abstract][Full Text] [Related]
4. Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia. Weng G; Zhang Y; Yu G; Luo T; Yu S; Xu N; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Shao R; Du X; Jin H; Liu Q J Intern Med; 2023 Mar; 293(3):329-339. PubMed ID: 36284445 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of Venetoclax and Azacitidine in Acute Myeloid Leukemia Compared to Azacitidine Monotherapy: Real-World Experience. Baba Y; Hida N; Sambe T; Abe M; Kabasawa N; Sakai H; Yoshimura K; Fukuda T Anticancer Res; 2024 May; 44(5):2003-2007. PubMed ID: 38677735 [TBL] [Abstract][Full Text] [Related]
7. Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Shimony S; Garcia JS; Keating J; Chen EC; Luskin MR; Stahl M; Neuberg DS; DeAngelo DJ; Stone RM; Lindsley RC Leukemia; 2024 Jul; 38(7):1494-1500. PubMed ID: 38538860 [TBL] [Abstract][Full Text] [Related]
8. Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia. Yin Z; Yao Z; Chen D; Zhang Y; Weng G; Du X; Lin D; Xiao J; Sun Z; Zhang H; Liang X; Guo Z; Zhao W; Xuan L; Jiang X; Shi P; Liu Q; Ping B; Yu G J Cancer Res Clin Oncol; 2024 Jul; 150(7):336. PubMed ID: 38969948 [TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study. Pasvolsky O; Shimony S; Ram R; Shimoni A; Shargian L; Avni B; Wolach O; Shochat T; Yerushalmi R; Amit O; Raanani P; Yeshurun M Ann Hematol; 2022 Feb; 101(2):379-387. PubMed ID: 34628534 [TBL] [Abstract][Full Text] [Related]
10. Less is more: An analysis of venetoclax and hypomethylating agent post-induction treatment modifications in AML. Boisclair S; Zhou E; Naing P; Thakur R; Jou E; Goldberg B; Gladstone DE; Allen SL; Kolitz JE; Chitty DW Leuk Res; 2024 Aug; 143():107545. PubMed ID: 38963990 [TBL] [Abstract][Full Text] [Related]
11. Corradi G; Forte D; Cristiano G; Polimeno A; Ciciarello M; Salvestrini V; Bandini L; Robustelli V; Ottaviani E; Cavo M; Ocadlikova D; Curti A Front Immunol; 2024; 15():1386517. PubMed ID: 38812504 [TBL] [Abstract][Full Text] [Related]
12. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301 [TBL] [Abstract][Full Text] [Related]
13. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study. Ram R; Amit O; Zuckerman T; Gurion R; Raanani P; Bar-On Y; Avivi I; Wolach O Ann Hematol; 2019 Aug; 98(8):1927-1932. PubMed ID: 31187237 [TBL] [Abstract][Full Text] [Related]
14. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097 [TBL] [Abstract][Full Text] [Related]
15. Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study. Weng G; Huang J; He X; Xue T; Yang L; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Jin H; Liu Q; Du X Ann Hematol; 2023 Dec; 102(12):3369-3381. PubMed ID: 37723307 [TBL] [Abstract][Full Text] [Related]
16. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience]. Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674 [No Abstract] [Full Text] [Related]
17. A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia. Murthy GSG; Saliba AN; Szabo A; Harrington A; Abedin S; Carlson K; Michaelis L; Runaas L; Baim A; Hinman A; Maldonado-Schmidt S; Venkatachalam A; Flatten KS; Peterson KL; Schneider PA; Litzow M; Kaufmann SH; Atallah E Haematologica; 2024 Sep; 109(9):2864-2872. PubMed ID: 38572562 [TBL] [Abstract][Full Text] [Related]
18. AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia. Todisco E; Papayannidis C; Fracchiolla N; Petracci E; Zingaretti C; Vetro C; Martelli MP; Zappasodi P; Di Renzo N; Gallo S; Audisio E; Griguolo D; Cerchione C; Selleri C; Mattei D; Bernardi M; Fumagalli M; Rizzuto G; Facchini L; Basilico CM; Manfra I; Borlenghi E; Cairoli R; Salutari P; Gottardi M; Molteni A; Martini V; Lunghi M; Fianchi L; Cilloni D; Lanza F; Abruzzese E; Cascavilla N; Rivellini F; Ferrara F; Maurillo L; Nanni J; Romano A; Cardinali V; Gigli F; Roncoroni E; Federico V; Marconi G; Volpi R; Sciumè M; Tarella C; Rossi G; Martinelli G; Cancer; 2023 Apr; 129(7):992-1004. PubMed ID: 36692409 [TBL] [Abstract][Full Text] [Related]
19. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. Venugopal S; Shoukier M; Konopleva M; Dinardo CD; Ravandi F; Short NJ; Andreeff M; Borthakur G; Daver N; Pemmaraju N; Sasaki K; Montalban-Bravo G; Marx KR; Pierce S; Popat UR; Shpall EJ; Kanagal-Shamanna R; Garcia-Manero G; Kantarjian HM; Kadia TM Cancer; 2021 Oct; 127(19):3541-3551. PubMed ID: 34182597 [TBL] [Abstract][Full Text] [Related]
20. Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents. Jin D; He J; Chen H; Wu W; Han X; Le J; Shu W; Yang Q; Pei S; Cai Z; He D Cancer Med; 2024 Jul; 13(14):e7378. PubMed ID: 39031026 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]